PharmaBoardroom

As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of…

The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the…

Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system…

Ida Sofie Jensen introduces the strong fundamentals underpinning the Danish innovative life sciences industry, including governmental support for…

Aymen Tamer, chairman and managing partner of historic Saudi healthcare firm Tamer Group, outlines how, informed by Saudi’s Vision 2030, the company…

Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure…

Mohamed Fawzy highlights how Pfizer’s work in Saudi Arabia dovetails with the country’s ambitious ‘Vision 2030’ transformation strategy, the…

Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and…

Mental health is a global crisis. 25 percent of the world’s population struggle with mental illness; and mental, neurological, and substance use…

John Baby of home rehabilitation device start-up WO:EX outlines how his firm’s products differ from others on the market through their…

A. Vogel CEO Dr Andy Suter outlines the Swiss herbal medicine market leader’s expansion in recent years, why it is prioritising R&D more than…

The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D…